← Russell 3000 cross-section

INFU InfuSystem Holdings, Inc

Trailing twelve months to 2026-06-30 · as filed 2026-08-04, not restated
Healthcare

Scale

Market cap
$240m
Revenue TTM
$143m
Net income TTM
$8m
Free cash flow
$23m
Composite score
62.1
Sector rank
#2786

Valuation

P / E
28.0
EV / EBITDA
9.8
EV / sales
1.8
FCF yield
9.56%
Earnings yield vs 10-yr
-1.18pp

Earnings yield vs 10-yr compares what the business earns per pound invested against the 4.73% a 10-year US Treasury note pays for no equity risk. Negative means you are paying up front for growth not yet delivered.

Quality and growth

Net margin
6.0%
EBITDA margin
18.4%
ROE
14.4%
ROIC
16.9%
Revenue growth
2.5%

Insider activity, last 90 days

Net open-market
$0.00m
Buyers
0
Sellers
0

Open-market purchases and sales only. Grants, option exercises, gifts and shares withheld for tax are excluded: they are how people are paid, not what they think.

What management said

We believe that the growth of continuous infusion therapy is driven by three factors: evidence of improved clinical outcomes; lower toxicity and side effects; and a favorable reimbursement environment. The increase included higher net revenues for the Patient Services segment partially offset by lower net revenues for the Device Solutions segment. Patient Services Patient Services net revenue of $24.8 million increased $3.3 million, or 15.2%, during the second quarter of 2026 compared to the prior year period. This increase was primarily attributable to additional treatment volume and increased third-party payer collections in Oncology and Wound Care. …InfuSystem Holdings, Inc, 10-Q, period ended 2026-06-30, filed 2026-08-04

Read the full passage →